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Abstract
West Nile virus (WNV) is a neurovirulent mosquito-borne flavivirus. High WNV virulence was mainly associated with lineage 1
strains, but recent outbreaks have unveiled circulation of highly virulent lineage 2 strains. Co-expression of flavivirus prM
and E glycoproteins drives the assembly of recombinant subviral particles (RSPs) that share antigenic features with virions.
Mouse immunization with lineage 1 WNV RSPs induced a potent humoral response against WNV with production of
neutralizing antibodies. A single inoculation of RSPs formulated with Al(OH)3 as adjuvant protected mice against a lethal
challenge with WNV strains from lineage 1 or 2. The cross-reactivity of the response elicited by these RSPs was analyzed
against the related flavivirus Usutu virus (USUV), which shares multiple ecological and antigenic features with WNV.
Immunization with WNV-RSPs increased specific, although low, antibody titers found upon subsequent USUV infection.
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Introduction
The genus Flavivirus within the Flaviviridae family comprises
more than 50 species of positive strand RNA viruses (http://www.
ictvonline.org/virusTaxonomy.asp). Flaviviruses constitute a
group of arboviruses including important human and animal
pathogens as Yellow fever virus (YFV), Dengue virus (DENV),
Tick-borne encephalitis virus (TBEV), Japanese Encephalitis virus
(JEV) or West Nile virus (WNV), as well as other neglected
pathogens of currently increasing interest, such as Usutu virus
(USUV) [1,2]. Both WNV and USUV are mosquito-borne
flaviviruses that share in nature an enzootic infectious cycle
between avian hosts and ornithophilic mosquito vectors [3,4]. Due
to different factors, including globalization of travel and trade,
changes in land use, climate warming and changes in vector
ecology, these flaviviruses have emerged in areas where they were
not previously detected originating outbreaks in humans, horses or
birds [1,5,6,7,8]. Currently, there is no vaccine or specific therapy
licensed in humans for either WNV or USUV, although different
WNV vaccine candidates have been approved for veterinary use
and multiple innovative approaches are being developed
[9,10,11].
WNV infects a wide range of vertebrate hosts. Although most
infections in humans are asymptomatic, WNV can induce a
variety of clinical signs that range from a mild flu-like febrile illness
(West Nile fever) to a severe neuroinvasive disease that can be fatal
[12,13]. In fact, a high proportion of patients that recover from
neuroinvasive disease carry severe long lasting sequelae [13].
Remarkably, the size and severity of WNV outbreaks has
increased in the last years, in some cases associated with viral
strains from lineage 2 WNV either in Africa, where this viral
lineage was endemic, or in Europe, where it had not been
previously detected [14,15,16,17,18]. Regarding USUV infection,
the case record is rather limited since it has been only circulating
in Africa until 2001, when it emerged in Europe [4,8]. This fact
together with that symptoms induced by USUV greatly vary
(including fever, rash, jaundice or meningoencephalitis) presum-
ably may have impaired its diagnosis in poorly industrialized
countries, where its circulation could be underestimated [4].
Indeed, almost no attention was paid to this virus until it emerged
in Europe causing avian mortality. However, since then, there is
increasing evidence of USUV circulation not only among
mosquitoes and birds, but also among horses [19,20,21] and
humans [22,23,24], including the report of severe neuroinvasive
infections [25,26,27]. These findings along with the similarities
between USUV and WNV ecology emphasize the need to be
cautious about the potential of USUV, and other emerging
flaviviruses, as a threat to human or animal health [1,2,4,28].
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Flavivirus virions are spherical particles about 50 nm in
diameter that contain a viral core constituted by the viral RNA
associated to the capsid protein C enclosed into a lipid envelope
that contains the two structural glycoproteins of the virion: M
(cleaved premembrane, prM) and E (envelope) [29]. The E
glycoprotein displays the major antigenic determinants of the
virion, being the target for most neutralizing antibodies. Both
WNV and USUV share common antigenic features between them
and with other flaviviruses included in the JEV serocomplex,
which is reflected in the potential to induce cross-reactive
antibodies [29,30]. The antibody cross-reactivity between different
flaviviruses is disadvantageous for diagnostic purposes because it
hampers identification of a specific pathogen through serologic
tests [3,13]. Nevertheless, cross-reactivity can be advantageous to
expand the protection spectrum of flavivirus vaccines against
different but antigenically related pathogens within the JEV
serocomplex [31]. However, to our knowledge no previous studies
addressing the cross-reactivity with USUV of the humoral
response induced by any WNV-vaccines have been reported.
Co-expression of the flavivirus prM and E glycoproteins induces
formation of virus-like particles commonly referred to as
recombinant subviral particles (RSPs) that, despite their reduced
diameter (around 30 nm), share multiple common antigenic and
immunogenic properties with whole virions [32,33,34,35]. Indeed,
initial approaches to test the potential use of RSPs as vaccine
candidates have been assessed with TBEV [36], JEV [37], Murray
Valley encephalitis virus (MVEV) [38] or WNV [33]. In this study
we have developed a cell line stably transfected with a plasmid
expressing the WNV prM and E proteins that constitutively
secreted WNV-RSPs to the culture medium. Immunization with a
single dose of these RSPs formulated with Al(OH)3 as adjuvant
protected mice against lethal challenge with lineage 1 WNV,




All animals were handled in strict accordance with the
guidelines of the European Community 86/609/CEE at the
biosafety animal facilities of the Instituto Nacional de Investigacio´n
Agraria y Alimentaria (INIA). The protocols were approved by the
Committee on Ethics of Animal Experimentation of INIA (permit
number 2013-015).
Cells, viruses, infections and virus titrations
All virus manipulations were performed in our biosafety level 3
(BSL-3) facilities. HeLa cells [39] and 293T (ATCC CRL-3216)
cells were grown in Dulbecco’s modified minimum essential
medium (DMEM) supplemented with 10% fetal bovine serum,
2 mM glutamine and penicillin-streptomycin. The origin and
passage history of the WNV lineage 1 strain NY99 (GenBank:
KC407666.1) has been previously described [5,40,41]. WNV
lineage 2 isolate SRB-Novi Sad/12 (GenBank: KC407673.1)
corresponds to a virus isolated from a goshawk found dead in
Serbia in 2012 [18]. The prototypic USUV strain SAAR-1776
(GenBank: AY453412.1) was used [42,43,44]. All viruses were
amplified in Vero cells [41,43]. Procedures for infections and virus
titration in semisolid agarose medium have been described
[41,43].
Antibodies and control sera
Mouse monoclonal IgG1 3.67G anti WNV E protein was from
Millipore (Temecula, CA). Mouse monoclonal IgG1 to GFP
(Roche, Manheim, Germany) was used as an irrelevant isotype-
matched control antibody. Rabbit polyclonal serum against WNV
M protein was from Imgenex (San Diego, CA). Control pooled
sera from experimentally WNV-infected mice [45] or red-legged
partridges [46], as well as appropriate negative controls from
uninfected animals were used. In addition, the following secondary
antibodies were employed: donkey anti-mouse IgG coupled to
Alexa Fluor 594 (Invitrogen; Carlsbad, CA), goat anti mouse or
anti-rabbit IgG coupled to horseradish peroxidase (Pierce
Biotechnology; Rockford, IL), goat anti-bird IgG coupled to
horseradish peroxidase (Bethyl Laboratories; Montgomery, TX),
goat anti-mouse IgG coupled to 5 nm colloidal gold (British
Biocell International; Cardiff, UK) and protein A coupled to 5 nm
colloidal gold (Cell Microscopy Center; Department of Cell
Biology, University Medical Center Utrech, The Netherlands).
Molecular cloning
Plasmid pcDNA-WNV encoding the signal peptide from the C
protein and the prM and E proteins from WNV-NY99 was
constructed as follows. First, viral RNA was extracted from tissue
culture medium of cells infected with WNV NY99 using the
NucleoSpin Viral RNA Isolation kit (Macherey-Nagel GmbH &
Co.; Du¨ren, Germany). The cDNA encoding the last 25 amino
acids from WNV anchored C protein (signal peptide) and
complete prM and E glycoproteins was amplified by reverse
transcription of viral RNA using SuperScript One-Step RT-PCR
with Platinum Taq (Invitrogen) and oligonucleotide primers
CAAGCTAGCGCCACCATGAGCTCAAAACAAAAGAAAA-
GAGG and GTTGGTACCCTAAGCGTGCACGTT CACGG
(restriction sites NheI and KpnI, start and stop codons and a
Kozac consensus sequence are indicated in italics, bold, and
underlined, respectively). The resultant cDNA fragment was
digested with NheI and KpnI (New England Biolabs; Ipswich,
MA) and ligated, using T4 DNA ligase (Promega; Madison, WI),
with plasmid pcDNA 3.1 (+) (Invitrogen) digested with the same
enzymes. The product of the ligation reaction was transformed
into E. coli DH5a as described [47]. Positive colonies were
obtained by selection in LB agar plates supplemented with
ampicillin. Plasmid DNA was purified from bacteria through
PureLink HiPure Plasmid Filter Maxiprep kit (Invitrogen). The
nucleotide sequence of pcDNA-WNV was verified by automated
nucleotide sequencing (Macrogen Europe; Amsterdam, The
Netherlands).
Transfections and stable cell line selection
HeLa cells were transfected with pcDNA or pcDNA-WNV
using Lipofectamine PLUS Reagent (Invitrogen), as described by
the manufacturer. For stable cell line selection, individual clones
were obtained by limit dilution of HeLa cells transfected with
pcDNA-WNV (48 h post-transfection) and grown in selective
medium containing 500 mg/ml of G-418 (Gibco). Cell clones were
screened for E protein expression by immunofluorescence and
immunodot assay as described below.
Purification of RSPs
Subviral particles were purified by sucrose gradient centrifuga-
tion as described [32], with minor variations. Briefly, culture
medium clarified at 150006g (30 min at 4uC) was centrifuged
through a 20% sucrose cushion at 1120006g (3.5 h at 4uC). The
pellet containing RSPs was resuspended in PBS and loaded onto a
12 ml 20–60% linear sucrose gradient (2560006g for 18 h at
4uC). Fractions of 0.5 ml were collected from the top of the
gradient. For mouse experiments, peak fractions containing E
protein were further purified by an additional sucrose gradient and
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peak fractions containing RSPs were pooled and dialyzed against
PBS to remove the sucrose. The amount of proteins in purified
RSP preparations was estimated by Bradford assay.
Mouse experiments
Groups of 6–12 eight-week old Swiss female mice were
inoculated intraperitoneally (i.p.) as described [36] with 200 ml
of a PBS solution containing 0.2, 2 or 10 mg of RSPs adsorbed to
0.2% (vol/vol) of aluminium hydroxide, Al(OH)3 (Alhydrogel,
InvivoGen, San Diego, CA). Control mice were inoculated with
the same volume of PBS alone or PBS plus Al(OH)3. To analyze
the induction of antibodies mice were bled at different time point
post-immunization and post-infection (p.i.). Mice were challenged
i.p. with 104 PFU/mouse of each strain of WNV or USUV and
monitored daily for signs of infection up to 15 days p.i. Animals
were kept with ad libitum access to food and water and those
exhibiting clear signs of disease as ruffled fur, hunching, hind limb
weakness, and paralysis, were anesthetized and sacrificed, as were
all surviving mice at the end of the experiment.
Plaque reduction neutralization assays (PRNT)
PRNT were essentially performed on Vero cells as previously
described [18]. Briefly, heat-inactivated pooled serum samples
were diluted in culture medium and filtered through 0.22 mm.
Neutralization was performed by incubating a fixed amount [100
plaque-forming unit (PFU)] of WNV NY99, SRB-Novi Sad/12 or
USUV with two-fold serial dilutions (starting from 1:20) of each
serum for 1 h at 37uC. Then the mixture was adsorbed for 1 h to
subconfluent Vero cell monolayers grown in six-well tissue culture
plates. After adsorption, culture medium was removed and cells,
overlaid with semisolid agarose medium, were incubated for 72 h,
fixed, and stained with crystal violet [41,43]. Titers were expressed
as the reciprocal of the serum dilution that inhibited plaque
formation by 90% (PRNT90), relative to samples incubated with
negative control pooled sera.
Enzyme-linked immunosorbent assays (ELISA)
Plates were coated with the antigen (RSPs or heat inactivated
virus) diluted in coating buffer (0.015 M Na2CO3, 0.030 M
NaHCO3; pH 9.6) and washed with PBS (RSPs) or PBS 0.05%
Tween 20 (inactivated virus). For heat inactivation, culture
medium of Vero cells infected with WNV-NY99 or USUV was
inactivated at 65uC for 2 h and mixed with 30% PEG 8000 in
0.4 M NaCl at the ratio of 2:1 (supernatant-PEG), overnight at
4uC with constant gentle rotation. Precipitate proteins were
recovered by centrifugation at 86716g (20 min at 4uC) dissolved
in ELISA coating buffer, sonicated and stored at 220uC. After
antigen coating, plates were blocked with 5% skimmed milk for
1 h at 37uC in PBS, washed and incubated with monoclonal
antibodies or specific sera (1 h at 37uC) diluted in blocking
solution, washed again and incubated with secondary antibodies
coupled to horseradish peroxidase (1 h at 37uC). ELISA was
developed using O-phenylene diamine dihydrochloride (Sigma; St.
Louis, MO) and H2O2. Results were expressed as the absorbance
at 492 nm (A492) or as positive/negative ratio (P/N) calculated by
dividing the mean absorbance of the test serum by the absorbance
of the negative control serum.
Enzyme-linked immunodot assays
Cell culture medium was adsorbed to a nitrocellulose mem-
brane by vacuum using a Bio-Dot apparatus (Bio-Rad; Hercules,
CA). Membrane was blocked with 3% skimmed milk in PBS and
incubated with primary antibodies diluted in 1% skimmed milk in
PBS. After three washes with PBS the membrane was incubated
with secondary antibodies coupled to horseradish peroxidase,
washed and proteins were detected by chemiluminiscence using an
ImageQuant LAS 4000 mini equipment (GE Healthcare, Buck-
inghamshire, United Kingdom).
Western blot
Purified RSPs were mixed with Laemmli sample buffer,
subjected to SDS-PAGE and electrotransferred onto a nitrocellu-
lose membrane. Membrane was blocked with 3% skimmed milk in
PBS, incubated with primary antibodies, washed three times with
PBS 0.05% Tween 20, and subsequently incubated with secondary
antibodies coupled to horseradish peroxidase. Membrane was
washed three times and proteins were detected by chemilumines-
cence as described above.
Immunofluorescence
HeLa cells grown on glass cover slips were transfected with
pcDNA or pcDNA-WNV and 24 h post-transfection were fixed
with 4% paraformaldehyde in PBS for 15 min. Cells were washed
with PBS and permeabilized with BPTG (1% BSA, 0.1% Triton
X-100, 1 M glycine in PBS) for 15 min, and then incubated with
primary antibody diluted in 1% BSA in PBS. After washing, cells
were incubated with fluorescently conjugated secondary antibody.
Nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI)
and samples were mounted with Fluoromount-G (SouthernBio-
tech, Birmingham, AL) and observed with an epifluorescencece
microscope.
Transmission electron microscopy
Negative staining of RSPs was performed as described for
TBEV RSPs in dialyzed samples containing the peak of the
gradient [32]. For immunolabelling and negative staining, samples
were adsorbed to ionized collodion-carbon coated grids, washed
with PBS and blocked with 10% fetal bovine serum in PBS for
5 min. Grids were incubated with primary antibodies diluted in
5% fetal bovine serum in PBS for 30 min, washed five times with
PBS and incubated with anti-mouse IgG or protein A coupled to
5 nm colloidal gold diluted in 5% fetal bovine serum in PBS for
30 min. Samples were then fixed with 1% glutaraldehyde in PBS
for 5 min, washed three times with bidistilled water and negatively
stained with 1% uranyl acetate for 2 min. Samples were examined
using a Jeol JEM-1010 electron microscope (Jeol, Japan) operated
at 80 kV and images were acquired using a digital camera 4K64K
TemCam-F416 (Tietz Video and Image Processing Systems
GmbH, Gauting, Germany).
Data analysis
To test the significance of the differences, analysis of the
variance (ANOVA) was performed with statistical package SPSS
15 (SPSS Inc, Chicago IL) applying Bonferroni’s correction for
multiple comparisons. Kaplan-Meier survival curves were ana-
lyzed by a logrank test using the statistical package GraphPad
PRISM v.2.01 (GraphPad Software Inc.; La Jolla, CA). The
median survival time (MST), defined as the time at which a
survival curve crosses the 50% survival point, was calculated for
every group of inoculated mice using GraphPad. Statistically
significant differences were considered at P,0.05. One asterisk (*)
or two asterisks (**) in the figures denote statistically significant
differences with P,0.05 or P,0.005, respectively.
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Results
Generation of a stable cell line expressing WNV envelope
glycoproteins and characterization of the secreted
antigens
Plasmid pcDNA-WNV encoding the 25 last amino acids of the
C-terminal hydrophobic sequence of the WNV-NY99 C protein
followed by the complete sequence of the prM and E proteins was
constructed (see Material and Methods for details). The expression
of WNV antigens following transfection of pcDNA-WNV was
verified by immunofluorescence staining using a monoclonal
antibody directed to the E glycoprotein (Figure 1A). In order to
analyze the secretion of WNV antigens to the extracellular
medium, the supernatant from HeLa or 293T cells transfected
with empty vector (pcDNA) or with pcDNA-WNV was harvested
at different times post-transfection and the presence of viral
antigens was determined by an enzyme-linked immunodot assay
(Figure 1B). Positive signals were obtained with the anti-E and the
anti-M antibodies at 24, 48 and 74 h post-transfection of both cell
lines with pcDNA-WNV but not with the empty vector. The
intensity of the signal increased with time pointing to an
accumulation of viral antigens in the medium of transfected
cultures.
Since processing of flavivirus structural protein precursors is
mediated by cellular proteases [48], the correct cleavage of the E
and M proteins was investigated. To this end, culture medium
from transfected cultures was concentrated by ultracentrifugation
through a 20% sucrose cushion and analyzed by Western blot
(Figure 1C). In these experiments, infectious WNV produced in
Vero cells and concentrated through a sucrose cushion was
included as a marker for the molecular size of WNV proteins.
Using an anti-E antibody, a single band with a mobility expected
for the E glycoprotein was detected in samples from culture
medium of both 293T and HeLa cells transfected with pcDNA-
WNV. When an anti-M antibody was used, the mature M protein
was detected in samples from HeLa and 293T cells, and an
additional band, similar to that of WNV particles, corresponding
to the prM protein was also observed. As transfection with
pcDNA-WNV resulted in correct expression and processing of
WNV antigens, a HeLa cell clone (HeLa3-WNV) stably transfect-
ed with this plasmid was obtained by limiting dilution and
selection with G-418. HeLa3-WNV cell line retained the
expression of WNV proteins upon freeze and thawing and over
serial passages. In fact, the expression of WNV E protein in the
culture medium could be detected up to, at least, 145 passages
(Figure 1D). When culture medium from HeLa3-WNV cultures
was further evaluated by ELISA using a monoclonal antibody to
the E protein, a positive signal could be detected up to a 1:640
dilution (Figure 1E). The viral antigens contained in the culture
medium of HeLa3-WNV were also recognized by pools of sera
from WNV-experimentally infected mice and birds (red-legged
partridges) in ELISA (Figures 1F and G). These results confirm
that HeLa3-WNV cells released to the culture medium viral
proteins recognized by antibodies from infected-animals of
different species.
To verify that the secreted proteins produced by HeLa3-WNV
were arranged in RSPs, culture medium was concentrated through
a 20% sucrose cushion followed by equilibrium centrifugation into
a linear 20–60% sucrose gradient (Figure 2A and B). The analysis
of the gradient fractions by immunodot revealed a single peak of E
protein that contained smooth spherical particles, as observed by
negative staining and transmission electron microscopy (Fig-
ure 2C). The size of these particles varied, the most abundant
particles ranging 20–40 nm in diameter, being the mean diameter
of 33610 nm (Figure 2D). The presence of WNV proteins in
these structures was further confirmed by negative staining and
immunolabelling of purified RSPs incubated with a monoclonal
anti-E antibody (Figure 2E, left panel). In addition, these
structures were also recognized by pooled sera from mice
experimentally infected with WNV (Figure 2E, right panel). This
further confirmed that RSPs displayed viral epitopes that could be
recognized by the antibodies developed in WNV-infected animals.
Taken together these results show that HeLa3-WNV cells stably
transfected with pcDNA-WNV produce WNV RSPs displaying
viral proteins.
Immunogenicity of the secreted WNV RSPs
Groups of six Swiss mice were inoculated intraperitoneally with
0.2, 2 or 10 mg per mouse of purified RSPs formulated with
Al(OH)3 as adjuvant, and boosted twice with a dose of 0.2 mg
(animals initially inoculated with 0.2 mg) or 2 mg (animals initially
inoculated with 2 or 10 mg) of RSPs at 19 (1st boost) and 41 (2nd
boost) days post-inoculation. A group of control animals inoculat-
ed with PBS plus Al(OH)3 was included. Mice were bled at 13, 33,
and 55 days post-immunization. The presence of anti-WNV IgGs
was assayed by an indirect ELISA using plates coated with heat
inactivated WNV. Control animals receiving PBS plus Al(OH)3 -
did not show detectable levels of anti-WNV IgG in serum samples
throughout the experiment (Figure 3A). Conversely, one of the six
animals receiving 0.2 mg of RSPs was positive after the first
inoculation (hereinafter referred to as inoculation) (Figure 3B) and
4 showed positive results after the first boost, while all the animals
developed anti WNV-IgG two weeks after the second boost. The
2 mg dose was enough to induce anti-WNV IgG in 5 out of 6
(83%) animals after inoculation, being all positive after the first
boost and showing a trend for titer increase upon the second boost
(Figure 3C). All mice immunized with 10 mg of RSPs developed
anti-WNV IgG and their titers increased after boosting (Fig-
ure 3D). The induction of WNV-neutralizing antibodies was
analyzed by PRNT (Table 1). Control mice receiving PBS plus
adjuvant did not show WNV-neutralizing antibodies, whereas
mice immunized with 0.2 mg of RSPs displayed detectable levels of
neutralizing antibodies after the first boost. Both groups of animals
receiving 2 or 10 mg of RSPs exhibited low although detectable
neutralizing antibody levels after inoculation (1:20), which were
markedly increased after first boost up to values .1:640. These
results confirmed that RSPs produced by the HeLa3-WNV cell
line could work as suitable immunogens since they were able to
induce anti-WNV antibodies after a single administration. As no
marked differences in the induction of specific IgG and
neutralizing antibodies were observed between animals immu-
nized with 2 or 10 mg of RSPs, a 2 mg dose was selected for
subsequent experiments involving viral challenge.
Evaluation of protection conferred by a single dose of
RSPs against infection with two genetically divergent
strains of WNV
WNV-induced death of experimentally inoculated mice is
associated with the virulence of the viral strain used [49,50,51].
Along this line, we first assessed the virulence in mice of the lineage
2 strain SRB-Novi Sad/12. This viral strain was recently isolated
from a dead bird in Serbia during the outbreak of WNV
neuroinvasive disease in East Europe in 2012 [18,52], and was
likely responsible of the first neuroinvasive human cases described
in the region. In these experiments the highly neurovirulent
lineage 1 strain NY99 often used as a challenge strain in vaccine
testing was included for comparison. Mice were inoculated
Lineage 1 and 2 WNV Vaccine and USUV Cross-Reaction
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intraperitoneally with 102 or 104 PFU of WNV NY99 or SRB-
Novi Sad/12. Both groups of mice exhibited signs of WNV disease
as ruffled fur or hunching and no significant differences related to
the mortality induced by both strains of WNV were noticed
(Figure 4A and B), pointing to SRB-Novi Sad/12 as a suitable
highly virulent challenge strain of WNV lineage 2.
The potential of RSPs as vaccine candidates was then evaluated
by inoculating mice with a single dose of 2 mg of RSPs combined
with Al(OH)3, which was the lowest dose tested that induced
detectable levels of neutralizing antibodies after a single inocula-
tion (Table 1). Animals were challenged with 104 PFU of WNV
NY99 or SRB-Novi Sad/12 two weeks post-inoculation (Figur-
es 4C and D). The percentage of surviving mice inoculated with
RSPs and challenged with WNV NY99 (Figure 4C) was 91.6%, a
value significantly higher than that of mice inoculated with PBS or
PBS plus Al(OH)3 (33.3%), as was the MST that also increased (.
15 days for RSPs, 10 days for PBS and PBS plus Al(OH)3).
Interestingly, all mice (100%, MST .15 days) inoculated with
RSPs survived the challenge with the heterologous WNV SRB-
Novi Sad/12, whereas only 33.3% (MST of 11 days) and 16.7%
Figure 1. Expression of WNV proteins encoded by plasmid pcDNA-WNV. (A) Immunofluorescence analysis of E protein expression. HeLa
cells were transfected with pcDNA or pcDNA-WNV and, 24 h later, fixed and processed for immunofluorescence using a monoclonal anti-E and a
secondary antibody coupled to Alexa Fluor 594. Nuclei were stained with DAPI. Scale bar 20 mm. (B) Analysis of WNV protein expression in the culture
medium from 293T or HeLa cells transfected with pcDNA-WNV by enzyme-linked immunodot assay. Both cell lines were transfected with pcDNA or
pcDNA-WNV and, 24, 48 or 72 h later, the culture medium was adsorbed onto a nitrocellulose membrane and detected using a monoclonal anti-E or
a polyclonal anti-M and the corresponding secondary antibodies coupled to horseradish peroxidase. (C) Western blot analysis of WNV proteins
released to the culture medium after transfection with pcDNA-WNV. HeLa or 293T cells were transfected with plasmid pcDNA-WNV and the viral
proteins in the culture medium were purified by ultracentrifugation through a 20% sucrose cushion. Proteins were blotted with the antibodies used
in panel (B). A control lane containing purified WNV from WNV-infected Vero cells was included. (D) Expression of E protein in the culture medium of
HeLa cells stably transfected with pcDNA-WNV (HeLa3-WNV). The E protein content in the culture medium from different passages of HeLa3-WNV
cells was determined by an enzyme-linked immunodot assay using a monoclonal antibody against E protein. (E) Analysis by ELISA of the reactivity of
WNV antigens released to culture medium of HeLa3-WNV cells. ELISA plates were coated with two-fold serial dilutions of culture medium from HeLa3-
WNV cells and incubated either with a monoclonal anti-E or an irrelevant isotype-matched control antibody. Samples were incubated with
appropriate secondary antibodies and developed using O-phenylene diamine dihydrochloride. ELISA results were expressed as the absorbance at
492 nm (A492). (F, G) Analysis of the reactivity of viral proteins secreted by HeLa3-WNV with pooled sera from experimentally infected mice (F) or
birds (G). ELISA plates were coated with a fixed dilution of HeLa3-WNV culture medium and incubated with two-fold serial dilutions of sera from
WNV-infected mice or red-legged partridges and the ELISA was performed as described in (E). Pooled sera from control uninfected animals were
included as negative controls.
doi:10.1371/journal.pone.0108056.g001
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(MST of 10.5 days) of mice inoculated with PBS plus Al(OH)3 or
PBS alone survived this challenge, respectively (Figure 4D).
Due to the relevance of neutralizing antibodies in WNV
protection, the induction of such antibodies was determined in the
mice shown in Figure 4. Animals immunized with RSPs displayed
at 3 and 4 days post-challenge neutralizing antibodies titers higher
than those of control mice inoculated with PBS or PBS plus
Al(OH)3, regardless the WNV strain used for challenge (Table 2).
At day 15 post-challenge the neutralizing antibody titers were
overall higher than 1:640 for all groups of surviving mice,
including both control and immunized animals, except for
neutralization of NY99 by mice inoculated with PBS and
challenged with NY99.
Analysis of the cross-reactive humoral response against
USUV in mice immunized with WNV RSPs
Since immunization with WNV-RSPs induced a protective
humoral response against genetically distant viral strains of WNV
such as SRB-Novi Sad/12, and different flaviviruses share
common antigenic determinants, the potential cross-reaction of
this immunization against other related flaviviruses was evaluated
using USUV. First, the induction of cross-neutralizing antibodies
after inoculation with WNV-RSPs was determined. While no anti-
USUV neutralizing antibodies were detected in PBS plus
Al(OH)3 sham immunized mice, or in mice immunized with
0.2 mg of WNV-RSPs, detectable titers were found in animals
immunized with 2 or 10 mg of WNV-RSPs after two boosts
(Table 3). Furthermore, sera from mice immunized with a single
dose of 2 mg of WNV-RSPs and challenged with WNV NY99 or
SRB-Novi Sad/12 showed titers of neutralizing antibodies at
15 days p.i. higher than those of non-immunized animals (PBS
alone or PBS plus Al(OH)3; Table 4). To address whether the
infection with USUV could mimic some features of a challenge
with WNV and stimulate the production of cross-reactive
Figure 2. Structural analyses of WNV antigens secreted by
HeLa3-WNV cells. (A) WNV proteins released to the culture medium
of HeLa3-WNV cells were purified by centrifugation through a 20%
sucrose cushion and loaded onto a 20–60% linear sucrose gradient. The
amount of E glycoprotein in each fraction of the gradient was
determined by enzyme-linked immunodot assay using a monoclonal
antibody against the WNV E protein. (B) Quantification of the integrated
density in each dot corresponding to the gradient fractions shown in
panel (A). (C) Negative stained TEM image of purified WNV RSPs
contained in peak fraction 11 of the gradient in panel (A). Scale bar:
50 nm. (D) Histogram showing the diameter of a total of 259 RSPs
visualized by transmission electron microscopy and negative staining as
in panel (C). (E) Purified RSPs were immunolabelled with either a
monoclonal anti-E (left panel) or a pooled sera from WNV-infected mice
(right panel), incubated with protein A or anti-mouse IgG coupled to
5 nm diameter colloidal gold. Samples were negatively stained and
observed by transmission electron microscopy. Scale bars: 50 nm.
doi:10.1371/journal.pone.0108056.g002
Figure 3. Induction of anti-WNV IgG in mice immunized with
WNV-RSPs. Groups of six Swiss mice were sham immunized by
inoculation with PBS plus Al(OH)3 (A) or immunized with 0.2 (B), 2 (C) or
10 (D) mg per mouse of purified RSPs formulated with Al(OH)3. Mice
were boosted twice with a dose of 0.2 mg (animals initially inoculated
with 0.2 mg) or 2 mg (animals initially inoculated with 2 or 10 mg) of
RSPs at 19 (1st boost) and 41 (2nd boost) days post-immunization. Mice
were bled about two weeks after each immunization (13, 33 and
55 days post-inoculation) and the presence of anti-WNV IgGs was
assayed by an indirect ELISA using plates coated with heat inactivated
WNV. ELISA titers are expressed as P/N ratios (see Material and
methods). Each point of the graph represents the P/N for a single
animal. Dashed lines denote the threshold of ELISA assays (P/N= 2.5).
doi:10.1371/journal.pone.0108056.g003
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antibodies in animals immunized with WNV-RSPs, groups of six
eight-week old Swiss mice were inoculated with PBS, PBS plus
Al(OH)3 or 2 mg of WNV-RSP and subsequently challenged with
104 PFU of USUV per mouse at 15 days post-immunization. This
USUV challenge did not induce mortality in adult mice in any of
the groups tested. When the outcome of the humoral response
against USUV was evaluated by ELISA (Figure 5) it was observed
that mice immunized with WNV-RSPs displayed low although
detectable levels of cross-reactive IgG with USUV (mean P/N of
2.560.4) in contrast to mice inoculated with PBS or PBS plus
adjuvant (mean P/N of 0.760.2 and 0.660.1, respectively) before
challenge with USUV (Figure 5A). The level of IgGs increased
after challenge with USUV (days 3, 4 and 7 post-challenge). in
WNV-RSPs inoculated animals, whereas only one animal of each
control group (PBS or PBS plus Al(OH)3) displayed very low, but
detectable levels of anti-USUV IgG at 7 days p.i. (Figure 5 B, C
and D), confirming that induction of IgG against USUV was
primed by immunization with WNV-RSPs. At the end of the
experiment, 15 days p.i. (Figure 5E), all USUV challenged mice
showed detectable levels of anti-USUV IgG, although these levels
were significantly higher for mice previously inoculated with
WNV-RSPs (mean P/N of 10.361.8) than for those inoculated
with PBS (mean P/N of 4.961.2) or PBS plus Al(OH)3 (mean P/N
of 5.360.9). The presence of anti-WNV antibodies was also
confirmed in these mice immunized with WNV-RSPs and
challenged with USUV (Figure 5F). The levels of anti-WNV
IgG increased with time following USUV infection, further
supporting that challenge with USUV acted as a boost for the
humoral response induced by inoculation with WNV-RSPs.
Likewise, mice immunized with WNV-RSPs developed higher
USUV neutralizing antibody titers upon challenge (day 15) than
those of control animals (Table 5). As expected, these animals
exhibited a higher increase on anti-WNV NY99 or SRB-Novi
Sad/12 neutralizing antibody titers, supporting that infection with
USUV boosted the antibody response elicited after immunization
with WNV-RSPs.
Table 1. Induction of WNV-neutralizing antibodies in mice immunized with different doses of RSPs.
Neutralizing antibody titer (PRNT90) on days post-inoculation
a
13 33 55
PBS+ Al(OH)3 Neg Neg Neg
RSPs 0.2 mg Neg 1:230 1:256
RSPs 2 mg 1:20 .1:640 .1:640
RSPs 10 mg 1:20 .1:640 .1:640
aSerum neutralization titers of pooled sera from six mice in each group correspond to PRNT90 values for WNV NY99. Samples were taken 13 days post-inoculation, two
weeks after first boost (33 days post-inoculation) and two weeks after second boost (55 days post-inoculation). Neg, negative (,1:20).
doi:10.1371/journal.pone.0108056.t001
Figure 4. Protection conferred by RSPs against WNV strains from lineage 1 or 2. (A, B) Comparison of the virulence in mice of two distinct
WNV isolates. Groups of 12 eight-week old Swiss female mice were infected in parallel with 102 (A) or 104 (B) PFU/mouse of WNV NY99 (lineage 1) or
SRB-Novi Sad/12 (lineage 2) and the mortality was recorded along time. (C, D) Protection conferred by the immunization with RSPs against a lethal
WNV challenge. Groups of 12 mice were inoculated intraperitoneally with PBS alone, PBS plus Al(OH)3, or 2 mg of purified RSPs plus Al(OH)3 and
challenged (two weeks post-inoculation) with 104 PFU/mouse of WNV NY99 (C) or SRB-Novi Sad/12 (D). Statistically significant differences are
indicated by one asterisk (*) for P,0.05 or two asterisks (**) for P,0.005. n.s. denotes not statistically significant differences.
doi:10.1371/journal.pone.0108056.g004
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Discussion
Co-expression of flavivirus glycoproteins in transfected cells
induces production of RSPs that are secreted into the culture
medium [32,33,34,35,53]. A widely used strategy to achieve this
goal is to express the tandem prM-E protein preceded by a signal
peptide as the C-terminal hydrophobic sequence of the C protein
of the same or another flavivirus [54,55] or by a different signal
peptide, even from an unrelated virus [34]. Accordingly, plasmid
pcDNA-WNV encoding the WNV C signal peptide followed by
the prM-E was constructed and shown to correctly express the
processed proteins. In order to provide noninfectious sources of
flaviviral antigens, a variety of cell lines continuously expressing
different prM and E glycoproteins have been reported
[33,34,37,54]. In this study we have generated a HeLa cell line
stably transfected with plasmid pcDNA-WNV as a noninfectious
Table 2. Induction of WNV-neutralizing antibodies in mice inoculated with RSPs upon challenge with WNV.
Neutralizing antibody titer (PRNT90) on days post-challenge
b
Challenge strain Groupa 3 4 15
NY99 PBS Neg 1:26 1:302
PBS+Al(OH)3 Neg 1:46 .1:640
RSPs 1:120 1:149 .1:640
SRB-Novi Sad/12 PBS Neg 1:68 .1:640
PBS+Al(OH)3 Neg 1:25 .1:640
RSPs 1:99 1:165 .1:640
aAnimals were immunized with a single dose containing 2 mg of RSPs and challenged two weeks post-inoculation.
bSerum neutralization titers of pooled sera from twelve mice in each group. Neutralization against the homologous viral strain selected for challenge (NY99 or SRB-Novi
Sad/12) are displayed. Neg, negative (,1:20).
doi:10.1371/journal.pone.0108056.t002
Figure 5. Induction of cross-reactive anti-USUV or anti-WNV IgGs in mice immunized with WNV RSPs and challenged with USUV.
Groups of six eight-weeks old Swiss female mice were sham immunized intraperitoneally with PBS or PBS plus Al(OH)3 or immunized with 2 mg of
WNV RSPs plus Al(OH)3 and challenged with 10
4 PFU of USUV two weeks later. (A to E). Anti-USUV antibodies in blood samples, collected at the days
post-challenge indicated in each case, detected by an indirect ELISA using plates coated with heat inactivated USUV. (F) Anti-WNV antibodies in
serum collected at different days post-challenge were detected by an indirect ELISA using plates coated with heat inactivated WNV. ELISA titers are
expressed as P/N ratios. Each point of the graph represents the P/N for a single animal. Solid lines represent the mean P/N of each group. Dashed
lines denote the threshold of ELISA assays (P/N= 2.5). Statistically significant differences are indicated by two asterisks (**) for P,0.005.
doi:10.1371/journal.pone.0108056.g005
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and easy to use platform for the production of RSPs. The physical
properties of these particles as well as their antigenicity were
characterized by means of ELISA, western blot, ultracentrifuga-
tion and transmission electron microscopy. It has been reported
that minor different subpopulations of flaviviral RSPs can be
separated by varying the purification conditions and that they
could differ in maturation status and immunogenicity [33,56]. Our
results show that using equilibrium sucrose density gradient
centrifugation a peak of protein containing RSPs that vary in size
but have a mean diameter of 30 nm was observed, a feature
consistent with previous findings derived from the structural
characterization of flavivirus RSPs [32,35,53]. The antigenicity of
these structures was confirmed by ELISA and immunogold
electron microscopy using anti-E antibodies or sera from WNV-
infected mice and birds.
A previous report had shown that inoculation of RSPs could
protect mice against challenge with a homologous lineage 1 WNV
strain after two administrations [33]. However, single dose
vaccines are desirable, especially for application during outbreaks,
in vaccination campaigns in poorly industrialized countries or for
wild animals. In addition to this, the recent epidemiologic scenario
of WNV has highlighted the need for verifying the efficacy of
available vaccines against viruses from lineages 1 and 2 [57,58,59].
Having in mind these considerations, the protection conferred by
immunization with our WNV RSPs against lethal challenge with
WNV virulent strains from both lineages was investigated.
Searching for an appropriate single dose vaccine formulation,
the immunogenicity of RSPs produced by the stable cell line was
assayed using an adjuvant, Al(OH)3, widely used for animal and
human vaccine formulation to enhance humoral immune response
[60,61], that constitutes a key player in WNV protection [62,63].
A single inoculation of RSP-based vaccine was enough to induce
circulating anti-WNV IgG and detectable titers of neutralizing
antibodies, which are known to be crucial to confer protection
against WNV [62,63]. Mice inoculated with a single dose of the
RSP-based vaccine showed a very high protection rate (91.6 and
100%, respectively) against lethal challenge with homologous and
heterologous WNV strains. This protection was associated with
the detection upon challenge of higher neutralizing antibody titers
in mice immunized with RSPs than those observed in sham
immunized animals; indicating that protection induced by the
RSPs was based on the induction of neutralizing antibodies. These
results evidence the feasibility of the RSP-based formulation here
described as vaccine candidates capable to induce protection
against WNV lineages 1 and 2. This finding is in agreement with
the cross-protection against lineages 1 and 2 conferred by different
WNV vaccines [57,58,59,64].
Vaccines against prominent flaviviruses such as YFV, JEV,
TBEV, WNV or DENV are currently available or under
development. Conversely, the development of vaccines specific
for flaviviruses that, so far, cause less-frequent diseases, such as
USUV, is unlikely [65]. In this regard, the cross-reactivity of WNV
vaccines against USUV could be helpful for the control of USUV
and other emerging pathogens. In fact, the potential of vaccines
against flaviviruses of the JEV serocomplex to induce cross-
reactive protective responses against antigenically related viruses
has been recently reviewed [31]. Since WNV and USUV share
multiple ecologic features, such as hosts and vectors, and co-
circulate in both Africa and Europe (see Introduction), the
potential induction of cross-reactive antibodies following vaccina-
tion with WNV-RSPs was analyzed. Vaccination of adult mice
with WNV-RSPs induced low, although detectable, levels of
Table 3. Induction of crossreactive USUV-neutralizing antibodies in mice immunized with different doses of WNV RSPs.
Neutralizing antibody titer (PRNT90) on days post-inoculation
a
13 33 55
PBS+Al(OH)3 Neg Neg Neg
RSPs 0.2 mg Neg Neg Neg
RSPs 2 mg Neg Neg 1:169
RSPs 10 mg Neg Neg 1:165
aSerum neutralization titers of pooled sera from six mice in each. Samples were taken 13 days post-inoculation, two weeks after first boost with 2 mg of RSPs (33 days
post-inoculation) and two weeks after second boost (55 days post-inoculation). Neg, negative (,1:20).
doi:10.1371/journal.pone.0108056.t003
Table 4. Induction of cross-neutralizing antibodies against USUV in mice inoculated with WNV RSPs upon challenge with WNV.
Neutralizing antibody titer (PRNT90) against USUV
b
Challenge strain Groupa Pre-challenge 3 4 15
NY99 PBS Neg Neg 1:75 1:86
PBS+Al(OH)3 Neg Neg Neg Neg
RSPs Neg Neg 1:75 .1:640
SRB-Novi Sad/12 PBS Neg Neg Neg 1:44
PBS+Al(OH)3 Neg Neg Neg 1:20
RSPs Neg Neg Neg 1:116
aAnimals were immunized with a single dose containing 2 mg of RSPs and challenged two weeks post-inoculation.
bSerum neutralization titers of pooled sera from six mice in each group correspond to PRNT90 values. Neg, negative (,1:20).
doi:10.1371/journal.pone.0108056.t004
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circulating IgG cross-reactive with USUV, and a boost on these
levels was observed upon infection with USUV. The cross-
reactivity of these antibodies with WNV was confirmed in ELISA
and neutralization tests. Unfortunately, protection studies of mice
immunized with WNV-RSPs against USUV challenge are
impaired as no lethal challenge model for USUV is available.
The levels of cross-reactive antibodies found were low and,
therefore, further work is required to elucidate if RSP-based
vaccines can effectively protect against antigenically related lethal
flaviviruses. Nevertheless, it should be noted that vaccines inducing
low or undetectable levels of neutralizing antibodies can protect
against flavivirus infection thanks to the anamnestic neutralizing
antibody response [66]. In addition, the induction of low levels of
circulating neutralizing antibody titers (1:10) against different
flaviviruses constitutes a widely used correlate with protection
among vaccinated humans (reviewed in reference [67]). On the
other hand, although cross-reactivity could be disadvantageous in
vaccine approaches against some flavivirus from other groups due
to antibody dependent enhancement of infection effect, this
phenomenon has not been documented among viruses from the
JEV serocomplex (in which WNV and USUV are included).
Therefore, the possibility of a cross-reactive vaccine for flaviviruses
within this group should be seriously considered, even though not
all flavivirus vaccines against JEV serocomplex viruses tested
induce effective cross-reacting responses [31]. For instance, there
are contradictory evidences supporting or not that JEV vaccines
can protect against infection with WNV or MVEV [65,68,69],
pointing to the necessity to evaluate each specific situation.
In this report, the feasibility of WNV-RSPs as a safe,
noninfectious, second-generation vaccine candidate against
WNV has been documented. The results here presented show
that a single dose of WNV-RSPs can induce a protective immune
response against WNV strains from lineage 1 and 2. In addition,
WNV-RSPs act as immunogens that can induce low, although
detectable, cross-reactive humoral responses against related
flaviviruses as USUV.
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